

![]() |
|||||||||||||
|
| All | Since 2020 | |
| Citation | 6651 | 4087 |
| h-index | 26 | 21 |
| i10-index | 174 | 83 |
Search
News & Updation
DEVELOPMENT AND CHARACTERIZATION OF SUSTAINED RELEASE MATRIX TABLET OF LOSARTAN POTASSIUM
Nikki Tripathi* and Dr. Shiv Garg
ABSTRACT The objective of the present work was to design, formulate and evaluate Losartan Potassium sustained release dosage form by incorporating it in a sustained release matrix made up of release retardant polymers which will prolong the drug release leading to minimize the peak and valley effect in the plasma and provide patient convenience. In the present study a total number of nine formulations each containing 50 mg of Losartan Potassium were prepared using wet granulation technique. All the nine formulations were subjected to in vitro dissolution studies using USP XXIII dissolution tester. Percentage cumulative drug release of drug in each formulation was determined based on the drug content uniformity. Formulation S3 best formulation because the maximum drug release was observed in S3 (95.1%) Formulation up to 20 hrs. Formulation S3 combinationshowed maximum swelling compared other formulation. The compatibility of the drug, polymers and excipients was determined by I.R. spectroscopy. Results showed that the drugs are compatible with polymers and all excipients. The granules were subjected to pre-compression evaluation such as angle of repose, loose bulk density, tapped bulk density and compressibility index. It was concluded that granules exhibited good compressibility and flow property. The tablets were subjected to various evaluation parameters such as thickness and diameter tests, weight variation test, hardness test, friability test, and drug content uniformity test. The results for all above evaluation parameters indicate that the values are within the range. Formulation S1-S9 showed zero order kinetics. Formulation S3 best formulation because the maximum drug release was observed in S3 (95.1%) Formulation up to 20 hrs and Formulation S3 combination showed maximum swelling compared other formulation. Keywords: Drug, Pharmacokinetics, Evaluation, Sustained release, Diffusion. [Download Article] [Download Certifiate] |
